People with asthma or COPD might one day benefit from new treatments that trigger bitter taste receptors.
Interestingly, bitter taste receptors are not just found in the mouth but also in other parts of the body, such as the airways. When activated, these receptors can open lung passages, making them a possible target for treating asthma or chronic obstructive pulmonary disease (COPD). In a recent study published in ACS’ Journal of Medicinal Chemistry, researchers have developed a powerful and selective compound that could pave the way for potential therapies.
Among the 25 different types of bitter taste receptors, the TAS2R14 subtype is one of the most widely distributed in tissues outside the mouth. Scientists are uncertain about the structure of the receptor, and they haven’t identified the particular compound or “ligand” in the body that activates it. However, a few synthetic compounds, such as the nonsteroidal anti-inflammatory drug (NSAID) flufenamic acidAny substance that when dissolved in water, gives a pH less than 7.0, or donates a hydrogen ion.” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]”>acid, are known to bind to and activate TAS2R14s.
But these compounds aren’t very potent, and they don’t have similar structural features. These difficulties make it challenging to create a better ligand. Nevertheless, Masha Niv, Peter Gmeiner, and colleagues used flufenamic acid as a starting point to design and synthesize analogs with improved properties. Next, the team wanted to extend that work to develop a set of even better TAS2R14 ligands.
Building on their earlier findings that certain types of structures enhanced potency, the researchers made several new variations. They tested these compounds in a cell-based assay that measures receptor activation. This approach revealed that replacing a phenyl ring with a 2-aminopyrimidine and substituting a tetrazole for a carboxylic acid group was a promising strategy. One of the new ligands was six times more potent than flufenamic acid, meaning less of the compound was needed to produce a similar response as the NSAID.
This ligand was also highly selective for TAS2R14 compared to non-bitter taste receptors, which could potentially minimize side effects. The new compounds will help shed light on the structure, mechanism, and physiological function of bitter taste receptors and guide the development of drug candidates to target them, the researchers say.
Reference: “Discovery of 2-Aminopyrimidines as Potent Agonists for the Bitter Taste Receptor TAS2R14” by Lukas Waterloo, Harald Hübner, Fabrizio Fierro, Tara Pfeiffer, Regine Brox, Stefan Löber, Dorothee Weikert, Masha Y. Niv and Peter Gmeiner, 27 February 2023, Journal of Medicinal Chemistry.
DOI: 10.1021/acs.jmedchem.2c01997
The authors acknowledge funding from the German Research Foundation.
Source: SciTechDaily
